Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

85 trials found

Recruiting 2,000,000 target

Helix Research Network

Helix

NCT06057181

Recruiting 200,000 target

Connect for Cancer Prevention Study (Connect)

National Cancer Institute (NCI)

NCT04609072

Recruiting NA 100,000 target

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

University of California, San Francisco

NCT02620852

Recruiting 33,000 target

General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

Sanford Health

NCT04477928

Recruiting 25,000 target

Avera Cancer Sequencing and Analytics Protocol (ASAP)

Avera McKennan Hospital & University Health Center

NCT05142033

Recruiting 20,000 target

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Sanford Health

NCT01793168

Recruiting 10,000 target

Umbrella Study for Analysis of Data Related to Patients With Cancer

Tempus AI

NCT06018753

Recruiting 4,500 target

Investigations of Reproductive Cancers in Women

PinkDx

NCT06527157

Recruiting 3,500 target

Genetic Epidemiology of Rotator Cuff Tears: The cuffGEN Study

University of Michigan

NCT04831164

Recruiting 2,500 target

MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.

Carolyn M Hettrich

NCT02075775

Recruiting 2,000 target

HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry

University of Kansas Medical Center

NCT06425848

Recruiting 1,065 target

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Merck Sharp & Dohme

NCT04165798

Recruiting NA 850 target

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

Boston Scientific Corporation

NCT07069738

Recruiting Phase 3 800 target

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Eli Lilly and Company

NCT07153471

Recruiting Phase 3 800 target

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Janssen Research & Development

NCT07225946

Recruiting Phase 1 768 target

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

NCT06324357

Recruiting Phase 3 710 target

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Daiichi Sankyo

NCT07022483

Recruiting NA 702 target

Melodi Matrix™ in Breast Reconstruction

Melodi Health

NCT06027996

Recruiting Phase 3 674 target

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Celcuity

NCT06757634

Recruiting 550 target

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Tempus AI

NCT07154823

Recruiting Phase 3 530 target

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Bristol-Myers Squibb

NCT06646276

Recruiting Phase 3 528 target

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

Melt Pharmaceuticals

NCT06383273

Recruiting Phase 3 520 target

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Merck Sharp & Dohme

NCT06305754

Recruiting Phase 3 500 target

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Imunon

NCT06915025

Recruiting Phase 3 500 target

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Revolution Medicines

NCT07252232

Recruiting 500 target

Pounce™ Thrombectomy System Retrospective Registry

SurModics

NCT05868161

Recruiting Phase 1 479 target

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Amgen

NCT04221542

Recruiting Phase 3 466 target

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Incyte Corporation

NCT07214779

Recruiting Phase 3 460 target

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

AbbVie

NCT06614192

Recruiting Phase 1 450 target

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Merck Sharp & Dohme

NCT04165070

Recruiting Phase 3 412 target

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Rakuten Medical

NCT06699212

Recruiting Phase 3 396 target

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Takeda

NCT06227910

Recruiting Phase 1 380 target

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Amgen

NCT07037758

Recruiting Phase 1 370 target

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Merck Sharp & Dohme

NCT02332668

Recruiting Phase 1 319 target

A Study of XMT-1660 in Participants With Solid Tumors

Mersana Therapeutics

NCT05377996

Recruiting Phase 1 315 target

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

NCT07160725

Recruiting 300 target

Perform Humeral System Study

Stryker Trauma and Extremities

NCT05067543

Recruiting Phase 1 258 target

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeiGene

NCT06257264

Recruiting Phase 2 222 target

A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse

Eli Lilly and Company

NCT07223840

Recruiting Phase 2 220 target

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Regeneron Pharmaceuticals

NCT06787612

Recruiting Phase 1 220 target

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Amgen

NCT06598306

Recruiting Phase 1 213 target

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

NCT06544655

Recruiting Phase 3 200 target

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Pfizer

NCT06616194

Recruiting Phase 1 200 target

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

ADC Therapeutics S.A.

NCT04970901

Recruiting Phase 1 200 target

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Amgen

NCT06898957

Recruiting NA 200 target

Evaluating Patient Reported Outcomes and Surgeon Satisfaction With Ziplyft™

Osheru

NCT07144761

Recruiting Phase 3 182 target

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Hoffmann-La Roche

NCT06084936

Recruiting 170 target

VIrtual STudy in Achondroplasia for the US (VISTA)

BioMarin Pharmaceutical

NCT06168201

Recruiting 160 target

An Ophthalmic Safety Study in Patients With Breast Cancer

AstraZeneca

NCT06767462

Recruiting NA 151 target

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

FemPulse Corporation

NCT07195656

Recruiting NA 140 target

Cognition After OSA Treatment Among Native American People (CATNAP)

Washington State University

NCT06227572

Recruiting NA 140 target

Together Overcoming Diabetes - Great Plains

Johns Hopkins Bloomberg School of Public Health

NCT06770673

Recruiting Phase 1 130 target

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Sapience Therapeutics

NCT05848739

Recruiting Phase 2 128 target

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Cumberland Pharmaceuticals

NCT05571059

Recruiting Phase 2 122 target

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Academic and Community Cancer Research United

NCT05168163

Recruiting Phase 2 120 target

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Regeneron Pharmaceuticals

NCT06465329

Recruiting NA 120 target

Contoura With Phorcides Compared to Wavefront Optimized LASIK

Daniel Terveen

NCT05486546

Recruiting 111 target

Type 1 Diabetes Extension Study

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02734277

Recruiting Phase 2 102 target

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ImmunoVaccine Technologies, Inc. (IMV Inc.)

NCT04920617

Recruiting NA 101 target

Ambulatory Long Length URodynamics Evaluation

Bright Uro

NCT07425015

Recruiting Phase 2 96 target

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Novartis Pharmaceuticals

NCT06655896

Recruiting Phase 2 90 target

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Merck Sharp & Dohme

NCT06731907

Recruiting Phase 1 90 target

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Merck Sharp & Dohme

NCT06395103

Recruiting Phase 1 90 target

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

BeiGene

NCT06803680

Recruiting Phase 2 87 target

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Atossa Therapeutics

NCT05607004

Recruiting Phase 3 81 target

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

Washington University School of Medicine

NCT04966481

Recruiting 80 target

Midwest Birth Outcomes and Indigenous American Pregnancy

Sanford Health

NCT06008561

Recruiting Phase 2 60 target

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Iovance Biotherapeutics

NCT06481592

Recruiting Phase 4 60 target

Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK

Vance Thompson Vision

NCT07155070

Recruiting Phase 1 60 target

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Compugen

NCT06888921

Recruiting NA 60 target

Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery

Vance Thompson Vision

NCT07155057

Recruiting NA 56 target

Measuring Outcomes of LASIK and EVO-ICL in Matched Populations

Vance Thompson Vision

NCT06700460

Recruiting NA 53 target

Mindfulness-Based Interventions Targeting First-Generation College Student Retention in Rural Environments

University of South Dakota

NCT06789731

Recruiting Phase 1 50 target

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

Merck Sharp & Dohme

NCT06941272

Recruiting Phase 2 48 target

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Deciphera Pharmaceuticals

NCT06619561

Recruiting NA 48 target

Healing Within: Mindfulness Smoking Cessation Intervention

National Heart, Lung, and Blood Institute (NHLBI)

NCT07013968

Recruiting NA 48 target

Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence

Black Hills Center for American Indian Health

NCT06357767

Recruiting Phase 2 45 target

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

ADARx Pharmaceuticals

NCT06989359

Recruiting NA 40 target

Safety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet Joint

InGeneron

NCT03513731

Recruiting Phase 2 40 target

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Faeth Therapeutics

NCT06463028

Recruiting NA 40 target

Exercise-induced Hypoalgesia and Proprioceptive Changes, Comparing Isometric to Isotonic Neck Exercises

University of South Dakota

NCT06465394

Recruiting NA 28 target

Lakota Family Acceptance Project

University of Michigan

NCT07326748

Recruiting Phase 2 25 target

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Otsuka Pharmaceutical Development & Commercialization

NCT06740526

Recruiting Phase 1 20 target

Study of BHV-1400 in IgA Nephropathy

Biohaven Therapeutics

NCT07054684

Recruiting NA 20 target

Improving Neurodevelopmental ouTcomes After Prenatal Cannabinoid in uTero Exposure

IDeA States Pediatric Clinical Trials Network

NCT06423664

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →